natural pharmaceuticals derived From Cannabis and other medicinal plants

Recently Received Notice of Authorization from Health Canada for the Conduct of its Clinical Trial with its PPTGR topical product

Sponsored
Tetra Bio-Pharma Inc. Profile

Tbp large

Tetra Bio-Pharma Reports Approval by Health Canada of its Phase I Trial of PPP001 (dried Cannabis)

We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies, said Dr. Chamberland, Chief Science Officer.

 Read Release

Other Recent Highlights

 

                   

Company Interviews

 

  

 

Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products

WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
  • Pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products

 

12 Month Stock Chart

Last changed at 16-Feb-2017 12:56PM by AGORACOM